The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

A statistically significantly lower risk of dementia or cognitive impairment was observed with GLP-1RAs, though not with SGLT2is or pioglitazone.

HealthDay News — Bausch + Lomb has announced a voluntary recall of intraocular lenses on its enVista platform due to the potential for an acute postoperative inflammatory reaction.

Artificial intelligence (AI) recommendations are more often rated as better quality than final recommendations of physicians for virtual care visits made by patients with respiratory, urinary, vaginal ...

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics Application (sBLA) for fremanezumab-vfrm to include the ...

The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.

Erzofri is an atypical antipsychotic that is administered once a month as an intramuscular injection by a health care professional.

Physicians should counsel patients considering whether to start treatment for chronic noncancer pain about benefits and harms of cannabis or cannabinoids.

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk ...

Patients carrying 2 copies of the APOE4 gene (APOE4/4 homozygotes) are more likely to develop AD earlier in life than those without APOE4.